NJ data regs may not pose threat for HIOs

New Jersey's Division of Consumer Affairs recommended tight controls on data-mining, among other limits designed to prevent conflicts of interest in medicine. But health information organizations, it would seem, only have to worry about some of those proposed rules.

The data-mining proposals accompany the division's Report on Physician Compensation Arrangements, which also covers areas such as gifts, financial disclosure and CME.

Attorney General Anne Milgram issued an endorsement.

However, in order to restrict the use and sale of prescriber-identifiable information for commercial purposes, the report recommends legislation, and this has little chance of advancing with Chris Christie, a Republican, set to replace Democrat John Corzine as governor.

The AG and other cabinet members are expected to tender resignations on inauguration day. Christie is pro-business and pro-pharma. As his chief of staff, he appointed Richard Bagger, a Pfizer executive and former state legislator.

Other data-related provisions could be enacted by the state's Board of Medical Examiners after a six-month comment period, though.

One calls for notifying doctors, upon renewing their licenses, that they can use AMA's opt-out program to prevent having Rx information sold by pharmacists. The Board of Pharmacy is also urged to amend its rules to require pharmacies to document doctors' consent to the sale of data.


You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.